2Carlin BI, Boder DR, Spirnak JP, et al. Role of finasteride in the treatment of recurrent heamaturia secondary to benign prostatic hyperplasia. Prostate, 1997,31 : 180-182.
3Foley SJ,Soloman LZ, Wedderburn AW .et al. A prospective study of the natural history of hematuria associated with benign prostatic hyperplasia and the effect of finasteride. J Uro1,2000,163:436-438.
4Vemeulen PB, Gasparini G, Fox SB, et al. Quantification of angiogenesis in solid human tumors:an international consensus on the methodology and criteria of evaluation. Eur J Cancer, 1996,32A : 2474-2484.
5Hahn RG. Dextran 70 and blood loss during transurethral resection of the prostate. Acta Anaes Scand, 1996,40 ;820-823.
6Lekas JM, Widmark BA, Damber JE. Decrement of blood flow preceeds the involution of the ventral prostate in the rat after castration.Urol Res, 1997,25:309-314.
7Takeshita S, Lu Hang, Brogi E, et al. Therapeutic angiogenesis. A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model. J Clin Invest, 1994,93:662-665.
8Leung D, Cachianes G, Kuarg W, et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science, 1989,246: 1306-1301.
9Yamamoto S,Konishi I, Tsuruta Y, et al. Expression of vascular endothelial growth factor (VEGF) during folliculegenesis and corpus luteum formation in the human ovary. Gynecol Endocrinol, 1997,11 :371-381.
10Haggstrom S,Wikstrom P, Bergh A, et al. Expression of vascular endothelial growth factor and its receptors in the rat ventral prostate and Dunning R3327 PAP adenocarcinoma before and after castration.Prostate, 1998,36:71-79.